346
Participants
Start Date
March 18, 2024
Primary Completion Date
December 31, 2024
Study Completion Date
March 26, 2025
Solriamfetol 300 mg
Solriamfetol tablets, taken once daily
Placebo
Placebo tablets, taken once daily
Clinical Research Site, Staten Island
Clinical Research Site, Brooklyn
Clinical Research Site, Rochester
Clinical Research Site, Media
Clinical Research Site, Philadelphia
Clinical Research Site, Hickory
Clinical Research Site, Jacksonville
Clinical Research Site, Orlando
Clinical Research Site, Orlando
Clinical Research Site, Orlando
Clinical Research Site, Hialeah
Clinical Research Site, Brandon
Clinical Research Site, Memphis
Clinical Research Site, Cincinnati
Clinical Research Site, Chicago
Clinical Research Site, Saint Charles
Clinical Research Site, Overland Park
Clinical Research Site, New Orleans
Clinical Research Site, Little Rock
Clinical Research Site, Oklahoma City
Clinical Research Site, Dallas
Clinical Research Site, Wichita Falls
Clinical Research Site, Friendswood
Clinical Research Site, Austin
Clinical Research Site, Las Vegas
Clinical Research Site, Los Angeles
Clinical Research Site, Torrance
Clinical Research Site, Bellflower
Clinical Research Site, Encino
Clinical Research Site, Sherman Oaks
Clinical Research Site, Montclair
Clinical Research Site, Upland
Clinical Research Site, Lemon Grove
Clinical Research Site, Oceanside
Clinical Research Site, Redlands
Clinical Research Site, Riverside
Clinical Research Site, Walnut Creek
Clinical Research Site, Everett
Clinical Research Site, Cromwell
Clinical Research Site, Boston
Lead Sponsor
Axsome Therapeutics, Inc.
INDUSTRY